top of page

Unlocking New Paths with Smart Peptides

SPIMA Therapeutics Develops Smart Peptide-Based Immunotherapies to Address Undruggable Targets
We aim at bringing to patients innovative medicines treating diseases
with challenging immunological avenues

About SPIMA Therapeutics

SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.

 

SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.


SPIMA Therapeutics is part of the nexus of Landmark Bioventures.

Join us in shaping the future of medicine, where discovery meets dedication.

Our Technology

Locking peptides into their bioactive α-helical conformation through site-specific introduction of a chemical brace


Our technology is centered on constraining short chains of amino acids — polypeptides — in a specific folded shape known as an α-helical conformation, which confers upon them unique drug-like properties including enhanced membrane permeability and stability

This makes Stapled Peptides promising candidates for intracellular protein-protein drug targeting

Our Pipeline

SPIMA Pipeline.png

Co-Founders - Executive Team 

Mohamed Haitham Ayad RPh, PhD

Chief Executive Officer 

 

Zaki Original_Portrait_edited.jpg

Zaki Sellam
MBA, Msc


Executive Chairman

  • Grey LinkedIn Icon
  • 20+ years of experience in Biotech

  • Expert in Immuno-Oncology Drug Development - created and developed several start-ups & signed more than 40 Deals

Haitham.jpg
  • Grey LinkedIn Icon
  • 20 years + of international experience in Pharma
     

  • Expert in early drug development, formulation/CMC and commercial-scale production

Co-Founders

Christian 1.jpg

Christian Jorgensen
MD, PhD

  • Grey LinkedIn Icon
  • Head of IRMB Institute of Research on Biotherapy
     

  • Director of IHU IMMUN4CURE Institute for Immunotherapy

Photos JM.jpg

Jean Martinez
PhD, Dr Sci

 

  • Grey LinkedIn Icon
  • Professor (Emeritus) at IBMM
     

  • Successfully discovered and developed a new drug

Florence_APPARAILLY_pic.jpg

Florence Apparailly
PhD

 
 

  • Grey LinkedIn Icon
  • INSERM Research Director

     

  • Expert in monocytes/macrophages’ biology in chronic joint inflammation and the design of targeted therapies

Muriel photo.jpg

Muriel Amblard
PhD  

 

  • Grey LinkedIn Icon
  • CNRS Researcher director, Head of the department of Amino Acids, Peptides and Proteins at IBMM
     

  • Expert in the chemistry of Peptides

Our Ecosystem & Partners

axlr-satt-montpellier-communique-presse-20190328.jpg
logo_ibmm_hd.jpg
Picture 1 copy.png
Logo institutes 3.png
Logo institutes 2.png
Logo SPIMA.png

80, avenue Augustin Fliche
34295 Montpellier

bottom of page